
High-Risk Breast Lesions (ADH, LCIS, Papilloma, Radial Scar): What Your Biopsy Means and Whether You Need Surgery
High-risk breast lesions are biopsy results that are not cancer but matter for two reasons: cancer may be hidden nearby where the needle did not sample (upgrade), and they raise the risk of future breast cancer. They include ADH, ALH/LCIS, papilloma, radial scar and flat epithelial atypia (FEA). Management depends on the lesion type and whether imaging and pathology agree (radiologic–pathologic concordance): some should be removed, others can be followed with imaging. At Namarak Hospital, breast surgeons, radiologists and pathologists review every case together according to international standards. Vacuum-assisted excision (VAE), which Namarak uses mainly for fibroadenomas, may be considered case by case for selected lesions such as papilloma or radial scar.
Each lesion and how it is managed
ADH (atypical ductal hyperplasia)
Abnormal, atypical proliferation of duct cells resembling small-volume DCIS. Most guidelines recommend surgical excision, because about 15–30% are upgraded to DCIS or invasive cancer at surgery. In selected very-low-risk cases, such as small calcifications almost completely removed at biopsy, observation may be considered. ADH raises future breast cancer risk about fourfold.
ALH and LCIS (lobular neoplasia)
Classic ALH or LCIS found incidentally with concordant imaging — surgery is not required; follow with exams and imaging
Pleomorphic or florid LCIS — behaves more like DCIS and should be excised with clear margins
LCIS is mainly a risk marker; it raises cancer risk by about 1–2% per year, in either breast
Papilloma (intraductal papilloma)
A growth inside a milk duct, often causing clear or bloody discharge from one nipple — see Nipple discharge
Papilloma without atypia, small, asymptomatic and concordant — can be followed with imaging
Symptomatic (e.g. bloody discharge), large or discordant — consider removal by surgery or VAE case by case
Papilloma with atypia — should be surgically removed
Radial scar / complex sclerosing lesion
A star-shaped lesion that can look like cancer on mammography. If adequately sampled and without atypia, it can be followed or removed by VAE case by case; with atypia, it should be excised.
Flat epithelial atypia (FEA)
Pure FEA that has been adequately sampled carries low risk and can be followed with imaging; excision is advised if many calcifications remain or ADH is also present.
Follow-up when surgery is not needed
Repeat imaging at about 6, 12 and 24 months to confirm stability
Remove the lesion if it grows or changes
Then screen as a higher-risk patient with yearly 3D mammography, ultrasound and automated breast ultrasound (ABUS); MRI may be added depending on overall risk
Lowering future cancer risk
People with ADH, ALH or LCIS should have a comprehensive breast cancer risk assessment and consider risk-reducing medication such as tamoxifen (including low-dose 5 mg for 3 years), raloxifene, or an aromatase inhibitor after menopause, which can roughly halve risk — see Breast cancer risk reduction options
Frequently asked questions (FAQ)
Does ADH mean I have cancer?
No. ADH is not cancer, but about 15–30% are upgraded to cancer at surgery, so most guidelines recommend excision. It also raises future breast cancer risk.
Does LCIS need surgery?
Classic LCIS found incidentally with concordant imaging does not need surgery and can be followed. Pleomorphic or florid LCIS should be excised.
Does every papilloma need to be removed?
No. A small, asymptomatic papilloma without atypia and with concordant imaging can be followed. Bloody nipple discharge or atypia warrants removal, by surgery or VAE as indicated.
Can VAE replace surgery?
VAE is used mainly for fibroadenomas. For selected high-risk lesions such as papilloma or radial scar without atypia, VAE may be considered case by case according to international standards; ADH and pleomorphic LCIS should be surgically excised.
How should I be screened after a high-risk lesion?
Yearly mammography with ultrasound, adding MRI in some cases depending on overall risk, and discussing risk-reducing medication with your doctor.
About Namarak Hospital
Namarak Hospital is a specialized breast and breast cancer hospital in Bangkok, providing complete care in one place — from diagnosis with 3D mammography, ultrasound, automated breast ultrasound (ABUS) and biopsy to comprehensive breast cancer treatment, including breast-conserving and reconstructive surgery, intraoperative radiotherapy (IORT), chemotherapy, targeted therapy and endocrine therapy, planned by a multidisciplinary team according to the latest international guidelines. See Breast cancer treatment: a complete guide, contact us on LINE, tel. +66 2 059 0245, or our Second Opinion service.
Related articles
References
American Society of Breast Surgeons. Resource Guide: Management of Breast Lesions with Atypia and High-Risk Lesions. ASBrS 2024
Catanzariti F, et al. High-risk lesions of the breast: concurrent diagnostic tools and management recommendations. Insights Imaging 2021;12:63
Elfgen C, et al. Third International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Virchows Arch 2023;483:5–20
DeCensi A, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia (TAM-01). J Clin Oncol 2019;37:1629–37
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction, 2026
Medically reviewed by: Namarak Hospital medical team · Last checked: 17 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.





Comments